Sudha Seshadri
Auto-generated profile, based on publicly available information

Sudha Seshadri

UT Health Science Center San Antonio

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
E(European Alzheimer'S Disease Initiative (Eadi)
European Alzheimer'S Disease Initiative (Eadi)
JLJean-Charles Lambert
Jean-Charles Lambert
G(Genetic And Environmental Risk In Alzheimer'S Disease (Gerad)
Genetic And Environmental Risk In Alzheimer'S Disease (Gerad)
A(Alzheimer's Disease Genetic Consortium (ADGC)
Alzheimer's Disease Genetic Consortium (ADGC)
C(Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
PAPhilippe Amouyel
Philippe Amouyel

1 September 2011 in Stroke
Verified
Journal Article
Closed access
PDF file
PGPhilip B. Gorelick
Philip B. Gorelick
ASAngelo Scuteri
Angelo Scuteri
SBSandra E. Black
Sandra E. Black
CDCharles DeCarli
Charles DeCarli
SGSteven M. Greenberg
Steven M. Greenberg
SSSudha Seshadri
Sudha Seshadri
Background and Purpose—: This scientific statement provides an overview of the evidence on vascular contributions to cognitive impairment and dementia. Vascular contributions to cognitive impairment and dementia of later life are common. Definitions of vascular cognitive impairment (VCI), neuropathology, basic science and pathophysiological aspects, role of neuroimaging and vascular and other associated risk factors, and potential opportunities for prevention and treatment are reviewed. This statement serves as an overall guide for practitioners to gain a better understanding of VCI and dementia, prevention, and treatment. Methods—: Writing group members were nominated by the writing group co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council Scientific Statement Oversight Committee, the Council on Epidemiology and Prevention, and the Manuscript Oversight Committee. The writing group used systematic literature reviews (primarily covering publications from 1990 to May 1, 2010), previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. After peer review by the American Heart Association, as well as review by the Stroke Council leadership, Council on Epidemiology and Prevention Council, and Scientific Statements Oversight Committee, the statement was approved by the American Heart Association Science Advisory and Coordinating Committee. Results—: The construct of VCI has been introduced to capture the entire spectrum of cognitive disorders associated with all forms of cerebral vascular brain injury—not solely stroke—ranging from mild cognitive impairment through fully developed dementia. Dysfunction of the neurovascular unit and mechanisms regulating cerebral blood flow are likely to be important components of the pathophysiological processes underlying VCI. Cerebral amyloid angiopathy is emerging as an important marker of risk for Alzheimer disease, microinfarction, microhemorrhage and macrohemorrhage of the brain, and VCI. The neuropathology of cognitive impairment in later life is often a mixture of Alzheimer disease and microvascular brain damage, which may overlap and synergize to heighten the risk of cognitive impairment. In this regard, magnetic resonance imaging and other neuroimaging techniques play an important role in the definition and detection of VCI and provide evidence that subcortical forms of VCI with white matter hyperintensities and small deep infarcts are common. In many cases, risk markers for VCI are the same as traditional risk factors for stroke. These risks may include but are not limited to atrial fibrillation, hypertension, diabetes mellitus, and hypercholesterolemia. Furthermore, these same vascular risk factors may be risk markers for Alzheimer disease. Carotid intimal-medial thickness and arterial stiffness are emerging as markers of arterial aging and may serve as risk markers for VCI. Currently, no specific treatments for VCI have been approved by the US Food and Drug Administration. However, detection and control of the traditional risk factors for stroke and cardiovascular disease may be effective in the prevention of VCI, even in older people. Conclusions—: Vascular contributions to cognitive impairment and dementia are important. Understanding of VCI has evolved substantially in recent years, based on preclinical, neuropathologic, neuroimaging, physiological, and epidemiological studies. Transdisciplinary, translational, and transactional approaches are recommended to further our understanding of this entity and to better characterize its neuropsychological profile. There is a need for prospective, quantitative, clinical-pathological-neuroimaging studies to improve knowledge of the pathological basis of neuroimaging change and the complex interplay between vascular and Alzheimer disease pathologies in the evolution of clinical VCI and Alzheimer disease. Long-term vascular risk marker interventional studies beginning as early as midlife may be required to prevent or postpone the onset of VCI and Alzheimer disease. Studies of intensive reduction of vascular risk factors in high-risk groups are another important avenue of research.

28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

14 February 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SSSudha Seshadri
Sudha Seshadri
ABAlexa Beiser
Alexa Beiser
JSJacob Selhub
Jacob Selhub
PJPaul F. Jacques
Paul F. Jacques
IRIrwin H. Rosenberg
Irwin H. Rosenberg
PWPhilip A. Wolf
Philip A. Wolf
In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia. Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies. A total of 1092 subjects without dementia (667 women and 425 men; mean age, 76 years) from the Framingham Study constituted our study sample. We examined the relation of the plasma total homocysteine level measured at base line and that measured eight years earlier to the risk of newly diagnosed dementia on follow-up. We used multivariable proportional-hazards regression to adjust for age, sex, apolipoprotein E genotype, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B12 and B6. Over a median follow-up period of eight years, dementia developed in 111 subjects, including 83 given a diagnosis of Alzheimer's disease. The multivariable-adjusted relative risk of dementia was 1.4 (95 percent confidence interval, 1.1 to 1.9) for each increase of 1 SD in the log-transformed homocysteine value either at base line or eight years earlier. The relative risk of Alzheimer's disease was 1.8 (95 percent confidence interval, 1.3 to 2.5) per increase of 1 SD at base line and 1.6 (95 percent confidence interval, 1.2 to 2.1) per increase of 1 SD eight years before base line. With a plasma homocysteine level greater than 14 μmol per liter, the risk of Alzheimer's disease nearly doubled. An increased plasma homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease.

3 April 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PHPaul Hollingworth
Paul Hollingworth
DHDenise Harold
Denise Harold
RSRebecca Sims
Rebecca Sims
AGAmy Gerrish
Amy Gerrish
JLJean-Charles Lambert
Jean-Charles Lambert
JWJulie Williams
Julie Williams
Julie Williams, Michael Owen and colleagues report staged follow-up and meta-analyses of genome-wide association studies for Alzheimer's disease from the GERAD+ consortium. They identify common variants at ABCA7 and MS4A6A/MS4A4E associated with Alzheimer's disease and support for several additional susceptibility loci. We sought to identify new susceptibility loci for Alzheimer's disease through a staged association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease Genetic Consortium (ADGC) in a companion paper. We undertook a combined analysis of four genome-wide association datasets (stage 1) and identified ten newly associated variants with P ≤ 1 × 10−5. We tested these variants for association in an independent sample (stage 2). Three SNPs at two loci replicated and showed evidence for association in a further sample (stage 3). Meta-analyses of all data provided compelling evidence that ABCA7 (rs3764650, meta P = 4.5 × 10−17; including ADGC data, meta P = 5.0 × 10−21) and the MS4A gene cluster (rs610932, meta P = 1.8 × 10−14; including ADGC data, meta P = 1.2 × 10−16) are new Alzheimer's disease susceptibility loci. We also found independent evidence for association for three loci reported by the ADGC, which, when combined, showed genome-wide significance: CD2AP (GERAD+, P = 8.0 × 10−4; including ADGC data, meta P = 8.6 × 10−9), CD33 (GERAD+, P = 2.2 × 10−4; including ADGC data, meta P = 1.6 × 10−9) and EPHA1 (GERAD+, P = 3.4 × 10−4; including ADGC data, meta P = 6.0 × 10−10).